Journal
ADVANCES IN THERAPY
Volume 31, Issue 3, Pages 276-288Publisher
SPRINGER
DOI: 10.1007/s12325-014-0104-1
Keywords
Efficacy; Epilepsy; Neurology; Partial seizures; Tolerability; Zonisamide
Funding
- Eisai Pharmaceuticals
- Janssen-Cilag
- UCB Pharma
- Beacon Pharmaceuticals Limited
Ask authors/readers for more resources
Although the majority of people with epilepsy have a good prognosis and their seizures can be well controlled with pharmacotherapy, up to one-third of patients can develop drug-resistant epilepsy, especially those patients with partial seizures. This unmet need has driven considerable efforts over the last few decades aimed at developing and testing newer antiepileptic agents to improve seizure control. One of the most promising antiepileptic drugs of the new generation is zonisamide, a benzisoxazole derivative chemically unrelated to other anticonvulsant agents. In this article, the authors present the results of a systematic literature review summarizing the current evidence on the efficacy and tolerability of zonisamide for the treatment of partial seizures. Of particular interest within this updated review are the recent data on the use of zonisamide as monotherapy, as they might open new therapeutic avenues.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available